Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03245840 · ClinicalTrials.gov registry record · Phase 3
Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)
A Phase 3 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 133
- Enrollment target
NCT03245840 is a Phase 3 study that was terminated before completion, run by Shire. The registered enrollment target is 133 participants.
The verdict
NCT03245840, a Phase 3 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 133 participants
- Enrollment target
Study Summary
This is a continuation study of Budesonide Oral Suspension (BOS) in adults and adolescents with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-302 extension study. The purpose of this study is to see if BOS is safe and well tolerated over the long-term in adolescents and adults with EoE.
Interventions
- DRUG Budesonide oral suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2017-10-05 |
| Est. Completion | 2022-04-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03245840
The ClinicalTrials.gov registry entry for NCT03245840 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Budesonide oral suspension is the first listed.
NCT03245840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03245840 about?
NCT03245840 is a clinical study titled "Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)". This is a continuation study of Budesonide Oral Suspension (BOS) in adults and adolescents with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-302 extension study. The purpose of this study is to see if BOS is safe and well tolerated over the long-term in adolescents a...
What is the current status of trial NCT03245840?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 133 participants. The study started on 2017-10-05. Estimated completion is 2022-04-26.
What interventions are being tested in trial NCT03245840?
The interventions under investigation include: Budesonide oral suspension (DRUG).
Who is sponsoring clinical trial NCT03245840?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.